ABX 1431

Drug Profile

ABX 1431

Alternative Names: ABX-1431 HCl; ABX1431

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abide Therapeutics
  • Developer Abide Therapeutics; University of Oxford
  • Class Analgesics; Anti-inflammatories; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists; Monoacylglycerol lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gilles de la Tourette's syndrome; Neurological disorders; Non-ulcer dyspepsia; Pain

Most Recent Events

  • 04 Oct 2017 Abide Therapeutics completes a phase I trial in Pain in United Kingdom (PO) (NCT02929264)
  • 07 Aug 2017 Abide Therapeutics terminates a phase I trial in Non-ulcer dyspepsia in Belgium due to recruitment challenges (PO) (NCT02875678)
  • 10 May 2017 Abide Therapeutics initiates enrolment in a phase I trial for Pain (Adjunctive therapy, Neuropathic pain) in United Kingdom (NCT03138421)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top